Vikas Prasad1, Aurora Sainz-Esteban2, Ruza Arsenic3, Ursula Plöckinger4, Timm Denecke5, Ulrich-Frank Pape6, Andreas Pascher7, Peter Kühnen8, Marianne Pavel6, Oliver Blankenstein8. 1. Department of Nuclear Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany. vikas.prasad@charite.de. 2. Department of Nuclear Medicine, Hospital Clínico Universitario Valladolid, Valladolid, Spain. 3. Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany. 4. Interdisziplinären Stoffwechsel-Centrum, Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany. 5. Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany. 6. Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany. 7. Department of General, Visceral and Transplant Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany. 8. Institute for Experimental Paediatric Endocrinology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
Abstract
PURPOSE: To explore the role of (68)Ga-DOTATATE/DOTATOC PET/CT (SR PET/CT) in patients with suspicion of or histopathologically proven pancreatogenic hyperinsulinaemic hypoglycaemia. METHODS: We included 13 patients with histopathologically proven or a high clinical suspicion of pancreatogenic hyperinsulinaemia. All the patients underwent a SR PET/CT scan. The results were correlated with histopathological findings. Normalization of blood glucose levels after resection of the pancreatic lesion, as well as a cytological and/or pathological diagnosis of insulinoma, was considered the diagnostic gold standard for insulinoma. The diagnosis of nesidioblastosis was based on exclusion of an insulinoma and conclusive pathological examination of a segment of the pancreas. Malignant insulinoma was defined as the presence of locoregional or distant metastases. RESULTS: Based on histopathology, 13 patients were found to have pancreatic hyperinsulinaemia: two patients had malignant insulinoma, eight had nonmetastasized insulinoma, and three had nesidioblastosis. SR PET was positive in 11 of the 13 patients (84.6 %) with a final diagnosis of endogenous pancreatic hypoglycaemia. Histopathological staining confirmed 16 foci of hyperinsulinism (insulin positivity). SR PET detected 14 of the 16 lesions, resulting in a sensitivity of 87 %. One intrapancreatic spleen was falsely diagnosed as insulinoma focus on SR PET, resulting in positive predictive value of 93.3 %. Immunohistochemical staining of somatostatin receptor (SSR) subtype 2a was available in ten specimens: two nesidioblastosis, and seven benign and one malignant insulinoma. Eight out of the ten specimens (80 %) stained strongly to moderately positive. Seven of the eight SSR2a-positive lesions were picked up on SR PET. Based on the results of SR PET/CT, nine patients achieved complete remission of the hypoglycaemic events during follow-up. CONCLUSION: This explorative study suggests that SR PET in combination with CT may play a significant role in the detection and management of patients with pancreatogenic hyperinsulinaemic hypoglycaemia. A large proportion of insulinomas express SSR2a, and a larger study is needed to fully assess the diagnostic accuracy of SR PET in patients with insulinoma and nesidioblastosis compared with current localizing studies used in clinical practice.
PURPOSE: To explore the role of (68)Ga-DOTATATE/DOTATOC PET/CT (SR PET/CT) in patients with suspicion of or histopathologically proven pancreatogenic hyperinsulinaemic hypoglycaemia. METHODS: We included 13 patients with histopathologically proven or a high clinical suspicion of pancreatogenic hyperinsulinaemia. All the patients underwent a SR PET/CT scan. The results were correlated with histopathological findings. Normalization of blood glucose levels after resection of the pancreatic lesion, as well as a cytological and/or pathological diagnosis of insulinoma, was considered the diagnostic gold standard for insulinoma. The diagnosis of nesidioblastosis was based on exclusion of an insulinoma and conclusive pathological examination of a segment of the pancreas. Malignant insulinoma was defined as the presence of locoregional or distant metastases. RESULTS: Based on histopathology, 13 patients were found to have pancreatic hyperinsulinaemia: two patients had malignant insulinoma, eight had nonmetastasized insulinoma, and three had nesidioblastosis. SR PET was positive in 11 of the 13 patients (84.6 %) with a final diagnosis of endogenous pancreatic hypoglycaemia. Histopathological staining confirmed 16 foci of hyperinsulinism (insulin positivity). SR PET detected 14 of the 16 lesions, resulting in a sensitivity of 87 %. One intrapancreatic spleen was falsely diagnosed as insulinoma focus on SR PET, resulting in positive predictive value of 93.3 %. Immunohistochemical staining of somatostatin receptor (SSR) subtype 2a was available in ten specimens: two nesidioblastosis, and seven benign and one malignant insulinoma. Eight out of the ten specimens (80 %) stained strongly to moderately positive. Seven of the eight SSR2a-positive lesions were picked up on SR PET. Based on the results of SR PET/CT, nine patients achieved complete remission of the hypoglycaemic events during follow-up. CONCLUSION: This explorative study suggests that SR PET in combination with CT may play a significant role in the detection and management of patients with pancreatogenic hyperinsulinaemic hypoglycaemia. A large proportion of insulinomas express SSR2a, and a larger study is needed to fully assess the diagnostic accuracy of SR PET in patients with insulinoma and nesidioblastosis compared with current localizing studies used in clinical practice.
Authors: Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2010-10 Impact factor: 9.236
Authors: W W de Herder; D J Kwekkeboom; R Valkema; R A Feelders; M O van Aken; S W J Lamberts; A J van der Lely; E P Krenning Journal: J Endocrinol Invest Date: 2005 Impact factor: 4.256
Authors: Martin Anlauf; Daniel Wieben; Aurel Perren; Bence Sipos; Paul Komminoth; Andreas Raffel; Marie L Kruse; Christian Fottner; Wolfram T Knoefel; Heiner Mönig; Philipp U Heitz; Günter Klöppel Journal: Am J Surg Pathol Date: 2005-04 Impact factor: 6.394
Authors: Damian Wild; Emanuel Christ; Martyn E Caplin; Tom R Kurzawinski; Flavio Forrer; Michael Brändle; Jochen Seufert; Wolfgang A Weber; Jamshed Bomanji; Aurel Perren; Peter J Ell; Jean Claude Reubi Journal: J Nucl Med Date: 2011-06-16 Impact factor: 10.057
Authors: Sandra Valéria de Sá; Maria Lúcia Corrêa-Giannella; Márcio Carlos Machado; Jean Jorge S de Souza; Maria Adelaide Albergaria Pereira; Rosely Antunes Patzina; Sheila Aparecida Coelho Siqueira; Marcel Cerqueira César Machado; Daniel Giannella-Neto Journal: Endocr Relat Cancer Date: 2006-03 Impact factor: 5.678
Authors: Benjamin Leroy-Freschini; Vincent Amodru; Pietro Addeo; Frédéric Sebag; Michel Vix; Laurent Brunaud; Marc Klein; Thibault Bahougne; Philippe Bachellier; Frédéric Castinetti; Bernard Goichot; Elodie Chevalier; David Taieb; Alessio Imperiale Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-07 Impact factor: 9.236
Authors: Lieke Joosten; Maarten Brom; Martin K H Schäfer; Otto C Boerman; Eberhard Weihe; Martin Gotthardt Journal: Sci Rep Date: 2017-05-11 Impact factor: 4.379